While the integration of pathological factors and molecular characteristics remains the optimal reference for diagnosis and treatment at present, the advent of IDH inhibitors has markedly improved survival outcomes in patients with IDH-mutant gliomas, establishing a new standard of care for this subset of tumors [20,21]. The gene discussed is IDH1; the disease is central nervous system cancer.